Safety of pharmacotherapy with Selective Serotonin Reuptake Inhibitors in patients on the autism spectrum - Case report
DOI:
https://doi.org/10.12923/2353-8627/2024-0025Keywords:
sertraline, SSRI, pharmacotherapy safety, ssri side effectsAbstract
Introduction: Depression is one of the most common mental disorders in the world, and treatment of this condition often includes the use of selective serotonin reuptake inhibitors (SSRI). Despite their widespread use and effectiveness, SSRI can cause adverse effects, especially in the pediatric and adolescent population, which requires close specialized supervision. A particularly vulnerable group are patients with autism spectrum disorders, where reactions to SSRI can be atypical and unpredictable.
Purpose: The aim of this study is to report an atypical response to sertraline treatment in a minor patient with a diagnosis of Asperger's syndrome, resulting in impulsive and aggressive behavior with legal consequences.
Case description: A 16-year-old patient with Asperger syndrome was treated with sertraline for depression and suicidal thoughts. Within three weeks of starting therapy, he developed severe symptoms of agitation, delusions and aggressive behavior that led to conflict with the law. The patient was referred for forensic psychiatric observation, where he was diagnosed with acute psychosis with symptoms of delusions of grandeur meeting the criteria for acute manic state F30.2. according to the ICD10 classification.
Conclusions: This case illustrates the risks of using SSRI in autistic patients, indicating the need for further studies on the safety of pharmacotherapy with this group of drugs in this population. The authors suggest special caution and the need to monitor children and adolescents taking SSRIs and to consider hospital conditions for the treatment of at-risk patients.
References
1. Joannès C, Redmond NM, Kelly-Irving M, Klinkenberg J, Guillemot C, Sordes F et al., The level of education is associated with an anxiety-depressive state among men and women – findings from France during the first quarter of the COVID-19 pandemic. BMC Public Health. 2023;23(1):1405.
2. World Health Organization. Depression and other common mental disorders: global health estimates. No. WHO/MSD/MER/2017.2. World Health Organization, 2017.
3. Chang J, Choi Y. Depression diagnosis based on electroencephalography power ratios. Brain Behav. 2023;21:3173.
4. Wan B, Wu Y, Ma N, Zhou Z, Lu W. Four modifiable factors that mediate the effect of educational time on major depressive disorder risk: A network Mendelian randomization study. PLoS One. 2023;18(7):0288034.
5. Mud Shukri MI, Minhat HS, Ahmad N, Ismail F, Kanthavelu C, Nurfarahin D et al., Prevalence and factors associated with depression, anxiety and stress in Malaysia during COVID-19 pandemic: A systematic review. PLoS One. 2023;18(7):0288618.
6. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). The Journal of clinical psychiatry. 2015;76(2):5356.
7. Nepal H, Black E, Bhattarai M. Self-Harm in Sertraline-Induced Akathisia. Prim. Care Companion CNS Disord. 2016;18(6).
8. Clevenger SS, Malhotra D, Dang J, Vanle B, IsHak WW. The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder. Therapeutic advances in psychopharmacology. 2018;8(1):49-58.
9. Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. StatPearls. Treasure Island (FL): StatPearls Publishing. 2022.
10. Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA et al., Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol. Int. 2021;13(3):387-401.
11. Robert L. Findling, Nora K. McNamara, Robert J. Stansbrey et al., The Relevance of Pharmacokinetic Studies in Designing Efficacy Trials in Juvenile Major Depression. Journal of Child and Adolescent Psychopharmacology. 2006;16:1-2.
12. Guy EJ, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs. 1999;57:507-533.
13. Hoffman R. Off-Label Uses for Selective Serotonin Reuptake Inhibitors. Am. Fam. Physician. 2005;71:43.
14. Stone KJ, Viera AJ, Parman CL, Off-label applications for SSRIs. Am. Fam. Physician. 2003;68:498-504.
15. Skånland SS, Cieślar-Pobuda A. Off-label uses of drugs for depression. Eur. J. Pharmacol. 2019;865:172732.
16. Beesdo-Baum K, Knappe S. Developmental epidemiology of anxiety disorders. Child. Adolesc. Psychiatr. Clin. N. Am. 2012;21(3):457-78.
17. https://rejestrymedyczne.ezdrowie.gov.pl › rpl/zoloft
18. Strawn JR, Dobson ET, Giles LL. Primary Pediatric Care Psychopharmacology: Focus on Medications for ADHD, Depression, and Anxiety. Curr. Probl. Pediatr. Adolesc. Health Care. 2017;47(1):3-14.
19. Rynn MA, Walkup JT, Compton SN, Walkup JT, Sakolsky DJ, Sherrill JT et al., Child/adolescent anxiety multimodal study: evaluating safety. J. Am. Acad. Child. Adolesc. Psychiatry. 2015;54(3):180-190.
20. Crawley SA, Caporino NE, Birmaher B, Ginsburg G, Piacentini J, Albano M et al., Somatic complaints in anxious youth. Child. Psychiatry Hum. Dev. 2014;45(4):398-407.
21. Hamill Skoch S, Mills JA, Ramsey L, Strawn JR. Letter to the editor: sleep disturbances in selective serotonin reuptake inhibitortreated youth with anxiety disorders and obsessive compulsive disorder-a Bayesian hierarchical modeling meta-analysis. J. Child. Adolesc. Psychopharmacol. 2021;31(5):387-388.
22. Nakonezny PA, Mayes TL, Byerly MJ, Emslie GJ. Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS). Journal of Psychiatric Research, 2015;68:346-353.
23. Garcia-Delgar B, Morer A, Varela E, Romero S, García M, Coffey BJ etal., Activation in Children and Adolescents Treated With Selective Serotonin Reuptake Inhibitors: A Weighty Reason? J. Clin. Psychopharmacol. 2018;38(5):475-480.
24. Safer DJ. Age-grouped differences in adverse drug events from psychotropic medication. J. Child. Adolesc. Psychopharmacol. 2011;21:299-309.
25. Telesnicki S, Patla M, Bołoz H, Depression as one of the conditionings of crime. Arch. Med. Sad. Krym. 2005;45:220-224.
26. Carlson GA, Mick E. Drug-induced disinhibition in psychiatrically hospitalized children. J. Child. Adolesc. Psychopharmacol. 2003;13:153-163.
27. Gabriele S, Sacco R, Persico AM. Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis. Eur. Neuropsychopharmacol. 2014;24:919-929.
28. Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2013;(8):004677.
29. Secci I, Petigas L, Cuenod A, Klauser P, Kapp C, Novatti A et al., Case report: Treatment-resistant depression, multiple trauma exposure and suicidality in an adolescent female with previously undiagnosed Autism Spectrum Disorder. Front Psychiatry. 2023;14:1151293.
30. Reiersen AM. Handen, B. Commentary on ‘Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)’. Evid. Based Child. Health Cochrane Rev. J. 2011;6:1082-1085.
31. Williams K, Wheeler DM, Silove N, Hazell P. Cochrane Review: Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Evid. Based Child. Health Cochrane Rev. J. 2011;6:1044-1078.
32. Kaprinis S, Parlapani E, Raikos N, Goulas A, Karpouza V. Psychotic episode associated with sertraline and drug-related delirium: a case report. J. Clin. Psychopharmacol. 2014;34(4):527-9.
33. Walker L. Sertraline-induced akathisia and dystonia misinterpreted as a panic attack. Psychiatric Services. 2002;53(11):1477-1478.
34. Healy D, Herxheimer A, Menkes DB. Antidepressants and violence: problems at the interface of medicine and law. PLoS. Med. 2006;3:372.
35. Tiihonen J, Lehti M, Aaltonen M, Kivivuori J, Kautiainen H, Virta LJ et al., Psychotropic drugs and homicide: A prospective cohort study from Finland. World Psychiatry. 2015;14(2):245-7.
36. Bouvy PF, Liem M. Antidepressants and lethal violence in the Netherlands 1994-2008. Psychopharmacology. 2012;222:499-506.
37. Marcotte DE, Markowitz S. A cure for crime? Psycho-pharmaceuticals and crime trends. NBER Working Paper. 2009;15354.
38. Mason SE. Prozac and crime: who is the victim? Am. J. Orthopsychiatry. 2002;72:445-455.
39. Merckelbach H, Jelicic M, de Ruiter C. De B. heeft een persoonlijkheidsstoornis en doodt zijn vriendin. MGv. 2009;64:747-759.
40. Tardiff K, Marzuk PM, Leon AC. Role of antidepressants in murder and suicide. Am. J. Psychiatry. 2002;159:1248-1249.
41. Barber CW, Azrael D, Hemenway D, Olson LM, Nie C, Schaechter J et al., Suicides and suicide attempts following homicide. Victim – suspect relationship, weapon type, and presence of antidepressants. Homicide Studies. 2008;12:285-297.
42. Molero Y, Lichtenstein P, Zetterqvist J, Gumpert CH, Fazel S. Selective Serotonin Reuptake Inhibitors and Violent Crime: A Cohort Study. PLoS Med. 2015;12(9):1001875.
43. Sato Y, Takatsu Y, Ito H, Kataoka K, Takeuchi Y, Matsumori A. SSRI Antidepressant Medications: Adverse; Effects and Tolerability. Heart Vessel. 1996;11:218-20.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
